HomeCompareSRSCQ vs ABBV

SRSCQ vs ABBV: Dividend Comparison 2026

SRSCQ yields 2000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRSCQ wins by $4.879226400974806e+39M in total portfolio value
10 years
SRSCQ
SRSCQ
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full SRSCQ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SRSCQ vs ABBV

📍 SRSCQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRSCQABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRSCQ + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRSCQ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRSCQ
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SRSCQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRSCQ + ABBV for your $10,000?

SRSCQ: 50%ABBV: 50%
100% ABBV50/50100% SRSCQ
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SRSCQ
No analyst data
Altman Z
1.8
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRSCQ buys
0
ABBV buys
0
No recent congressional trades found for SRSCQ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRSCQABBV
Forward yield2000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.879226400974806e+39M$102.3K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.879195005460081e+39M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SRSCQ vs ABBV ($10,000, DRIP)

YearSRSCQ PortfolioSRSCQ Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,550$430.00+$200.00MSRSCQ
2$3,738,731,768,458$3,738,517,757,009.35$13,472$627.96+$3738731.75MSRSCQ
3$65,315,062,866,930,490$65,311,062,423,938,240.00$15,906$926.08+$65315062866.91MSRSCQ
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$19,071$1,382.55+$1066400830062625.00MSRSCQ
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$23,302$2,095.81+$16272182796453826560.00MSRSCQ
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$29,150$3,237.93+$2.3205424011366188e+23MSRSCQ
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$37,536$5,121.41+$3.0927990661046884e+27MSRSCQ
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$50,079$8,338.38+$3.8524105697352695e+31MSRSCQ
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$4.484688260147987e+35MSRSCQ
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.879226400974806e+39MSRSCQ

SRSCQ vs ABBV: Complete Analysis 2026

SRSCQStock

Sears Canada Inc. operates as a multi-format retailer in Canada. The company operates department stores that offer various merchandise, including women's, men's, and children's apparel, as well as nursery products, cosmetics, jewelry, footwear, and accessories; and home furnishings and mattresses, home décor, lawn and garden, hardware, leisure, seasonal products, toys, floorcare, sewing, and various appliances. It also operates home stores, which provide furniture, mattresses and box-springs, and various appliances; hometown stores that offer various appliances, furniture, mattresses and box-springs, and outdoor power equipment; outlet stores, which provide clearance merchandise and surplus big-ticket items; and appliance specialty stores. In addition, the company offers a range of home services, such as carpet and duct cleaning, installation and assembly of heating and cooling equipment, custom window coverings, windows and doors, and other products purchased at its stores. Further, it provides logistics, product repair, travel, home improvement, insurance, and licensing services, as well as wireless and long distance plans. Additionally, the company operates optical centers and portrait studios; and catalogue and Internet channels. As of April 26, 2017, it had a network of 95 full-line department stores; 141 specialty stores comprising 26 Sears Home stores, 14 outlet stores, 69 Hometown stores, and 32 Corbeil stores; 62 Sears Travel offices; and approximately 800 merchandise pick-up locations for orders placed through the catalogue or online at sears.ca. The company was formerly known as Simpsons-Sears Limited and changed its name to Sears Canada Inc. in May 1984. Sears Canada Inc. was founded in 1952 and is headquartered in Toronto, Canada.

Full SRSCQ Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SRSCQ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRSCQ vs SCHDSRSCQ vs JEPISRSCQ vs OSRSCQ vs KOSRSCQ vs MAINSRSCQ vs JNJSRSCQ vs MRKSRSCQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.